Guo J H, Song S T, Xu Z L
Cancer Research Center, North Taiping Road Hospital, Beijing.
Zhonghua Zhong Liu Za Zhi. 1994 Jan;16(1):56-8.
A comparative study was performed in 37 patients with breast cancer who received high doses of cisplatin (100 mg/m2, I.V. drip) accompanied by two different hydration protocols. The new hydration protocol is based on the study of relationship between the pharmacokinetic parameters of plasma and urinary platinum concentration and the cisplatin-induced nephrotoxicity. In the new hydration protocol the diuretic drugs were given twice- amid and twelve hours after the cisplatin infusion instead of giving once--immediately after the cisplatin infusion, and 1,000ml drinking water was given by p.o. before taking cisplatin. Because of the increase in urinary volume the peak levels of urinary platinum were decreased from 47.34 micrograms/ml to 13.49 micrograms/ml, so that the rate of the nephrotoxicity was reduced from 36.8% (7/19) to 5.6% (1/18). The results suggest that the new hydration protocol is more effective than that previously used to protect against cisplatin nephrotoxicity.
对37例接受高剂量顺铂(100mg/m²,静脉滴注)并伴有两种不同水化方案的乳腺癌患者进行了一项对比研究。新的水化方案基于对血浆药代动力学参数、尿铂浓度与顺铂诱导的肾毒性之间关系的研究。在新的水化方案中,利尿药物在顺铂输注后6小时和12小时各给药一次,而不是在顺铂输注后立即给药一次,并且在服用顺铂前口服1000ml饮用水。由于尿量增加,尿铂的峰值水平从47.34微克/毫升降至13.49微克/毫升,因此肾毒性发生率从36.8%(7/19)降至5.6%(1/18)。结果表明,新的水化方案在预防顺铂肾毒性方面比以前使用的方案更有效。